<DOC>
	<DOCNO>NCT03018509</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , pharmacokinetics pharmacodynamic effect JTE-451 administer 4 week subject active plaque psoriasis .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacodynamics &amp; Pharmacokinetics JTE-451 Active Plaque Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<criteria>Minimum two psoriatic plaque ( i.e. , one clinical target lesion one biopsy target lesion ) . Each two target lesion must psoriatic lesion severity sum ( PLSS ) ≥6 Body mass index ( BMI ) 18 38 kg/m2 ( inclusive ) Prior exposure &gt; 2 systemic biologic agent and/or small molecule include investigational therapy treatment psoriasis discontinue systemic biologic agent and/or small molecule antipsoriasis therapy include investigational therapy due lack efficacy ; Subjects significant health problem , plaque psoriasis ( determined medical history , physical examination , chest Xray , vital sign 12lead ECG ) could either interfere study evaluation place subject undue risk ; Presence erythrodermic psoriasis , pustular psoriasis , guttate psoriasis , medicationinduced psoriasis Visit 1 ; Conditions ( e.g. , clinicallysignificant eczema severe acne target lesion area ) would interfere study evaluation ; Positive quantiFERON®TB Gold test , negative chest Xray finding tubercle bacillus ( TB ) lack evidence active latent TB ; History clinicallysignificant infection ( e.g. , required oral antimicrobial therapy ) within 4 week prior Visit 2 ; Subjects clinical laboratory test result within normal reference range ( i.e. , deem clinically significant ) clinically acceptable Investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>JTE-451</keyword>
	<keyword>psoriasis</keyword>
</DOC>